Immuron Limited - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
IMRN Nasdaq 2834 www.immuron.com.au

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immuron Limited

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance - Jan 15th, 2025 11:00 am
Immuron Announces Travelan® Clinical Trial Update - Jan 14th, 2025 11:00 am
Hartshead Resources And 2 Other Promising Penny Stocks On The ASX - Jan 14th, 2025 7:05 am
UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing - Dec 6th, 2024 2:17 pm
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th - Dec 6th, 2024 1:35 pm
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing - Dec 3rd, 2024 8:45 pm
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th - Dec 2nd, 2024 11:00 am
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event - Nov 21st, 2024 11:33 pm
Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event - Nov 18th, 2024 1:30 pm
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now - Oct 29th, 2024 11:00 am
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference - Oct 16th, 2024 10:00 am
Immuron Travelan® continued strong sales growth - Oct 15th, 2024 10:00 am
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - Oct 4th, 2024 10:30 am
Immuron Full Year 2024 Earnings: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023) - Oct 3rd, 2024 8:36 pm
Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now - Sep 24th, 2024 11:00 am
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - Sep 5th, 2024 3:54 pm
Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now - Aug 21st, 2024 11:00 am
US DoD grants $2.3m to Immuron for military version of anti-diarrhoeal Travelan - Aug 19th, 2024 3:03 pm
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® - Aug 16th, 2024 10:00 am
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference - Aug 15th, 2024 10:14 pm